Online inquiry

IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3561MR)

This product GTTS-WQ3561MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MIF gene. The antibody can be applied in Inflammatory conditions research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002415.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4282
UniProt ID P14174
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ3561MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15071MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SSS-23
GTTS-WQ5793MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ6465MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P23
GTTS-WQ7288MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FPA-008
GTTS-WQ13319MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ11923MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MLN2045
GTTS-WQ1991MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ9646MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW